LUND, Sweden -- Phase Holographic Imaging (PHI) announces a collaboration agreement with Northeastern University of Boston. PHI will provide Northeastern with HoloMonitor technology for establishing novel cell analysis applications and techniques based on PHI's non-invasive time-lapse imaging cytometry technology. Northeastern and PHI anticipate extending the program to create a regional center of excellence - an educational resource providing training for scientists using time-lapse cytometry techniques and to foster cross-disciplinary collaborations in cell-based research.
"We are pleased to partner with PHI to expand the services offered by the Department's Core Imaging and Cytometry facility, which serves as an important intellectual and technological resource for both Northeastern and the academic and industrial biotechnology communities in the Boston area. The agreement with PHI represents the next step in establishing collaborative links with the life sciences industry and positioning Northeastern as a comprehensive imaging cytometry and technology center in line with other Centers of Research Excellence affiliated with the Department," said Mansoor Amiji, Distinguished Professor and Chair of the Department of Pharmaceutical Sciences, Northeastern University.
"PHI's technology brings us the capability to visualize and quantify cells without stains that can interfere with cellular physiology. The ability to obtain holographic time-lapse videos with all of the cells in focus allows us to identify specific stages of the cell cycle affected by experimental pharmacological compounds," added Ed Luther, manager of Northeastern's Core Imaging and Cytometry facility.
"The HoloMonitor® technology is a strictly non-invasive method. Live cellular events can not only be visualized but also quantified without the use of stains in both single measurements and long-term studies. We look forward to support Northeastern's presentation of what we believe will be ground results," said Egelberg.
Phase Holographic Imaging (PHI) is the leader in the development of proprietary ground-breaking holographic time-lapse cytometry instrumentation and software. With the first instrument introduced in 2011, the company today offers a range of products for long-term quantitative analysis of cellular dynamics that circumvent the drawbacks of traditional methods requiring toxic stains. Headquartered in Lund, Sweden, PHI trades through a network of international distributors. Committed to promoting the science and practice of time-lapse cytometry, PHI is actively expanding its customer base and scientific collaborations in cancer research, inflammatory and autoimmune diseases, stem cell biology, gene therapy, regenerative medicine and toxicological studies.
For additional information, visit http://www.phiab.se